PL3331877T3 - Pochodna pirazolopirymidyny i jej zastosowania - Google Patents

Pochodna pirazolopirymidyny i jej zastosowania

Info

Publication number
PL3331877T3
PL3331877T3 PL16753709T PL16753709T PL3331877T3 PL 3331877 T3 PL3331877 T3 PL 3331877T3 PL 16753709 T PL16753709 T PL 16753709T PL 16753709 T PL16753709 T PL 16753709T PL 3331877 T3 PL3331877 T3 PL 3331877T3
Authority
PL
Poland
Prior art keywords
pyrimidine derivative
pyrazole pyrimidine
pyrazole
derivative
pyrimidine
Prior art date
Application number
PL16753709T
Other languages
English (en)
Inventor
Yinon Ben Neriah
Guy BRACHYA
Ido BURSTAIN
Waleed MINZEL
Irit SNIR-ALKALAY
Joseph Vacca
Dansu Li
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Publication of PL3331877T3 publication Critical patent/PL3331877T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16753709T 2015-08-04 2016-08-04 Pochodna pirazolopirymidyny i jej zastosowania PL3331877T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562200846P 2015-08-04 2015-08-04
US201562268750P 2015-12-17 2015-12-17
PCT/IL2016/050852 WO2017021969A1 (en) 2015-08-04 2016-08-04 Pyrazole pyrimidine derivative and uses thereof
EP16753709.1A EP3331877B1 (en) 2015-08-04 2016-08-04 Pyrazole pyrimidine derivative and uses thereof

Publications (1)

Publication Number Publication Date
PL3331877T3 true PL3331877T3 (pl) 2022-01-31

Family

ID=56738143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16753709T PL3331877T3 (pl) 2015-08-04 2016-08-04 Pochodna pirazolopirymidyny i jej zastosowania

Country Status (23)

Country Link
US (4) US10376511B2 (pl)
EP (1) EP3331877B1 (pl)
JP (1) JP7083309B2 (pl)
KR (1) KR102698366B1 (pl)
CN (1) CN108137562B (pl)
AU (2) AU2016304464B2 (pl)
CA (1) CA2994644A1 (pl)
CY (1) CY1124898T1 (pl)
DK (1) DK3331877T3 (pl)
ES (1) ES2901349T3 (pl)
HR (1) HRP20211949T1 (pl)
HU (1) HUE057607T2 (pl)
IL (1) IL257282B (pl)
LT (1) LT3331877T (pl)
MX (1) MX384172B (pl)
PL (1) PL3331877T3 (pl)
PT (1) PT3331877T (pl)
RS (1) RS62728B1 (pl)
RU (1) RU2735522C2 (pl)
SI (1) SI3331877T1 (pl)
SM (1) SMT202100720T1 (pl)
WO (1) WO2017021969A1 (pl)
ZA (1) ZA201800671B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62728B1 (sr) * 2015-08-04 2022-01-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivat pirazol pirimidina i njegove upotrebe
WO2018142393A1 (en) 2017-02-01 2018-08-09 Yissum Research Development Company Of The Hebrew N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
KR20200130287A (ko) * 2018-02-08 2020-11-18 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
EP3976600B1 (en) * 2019-06-03 2026-05-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Non-hygroscopic crystalline salts of a pyrazole compound, pharmaceutical compositions containing them and their use
CN114127058B (zh) * 2019-07-04 2024-06-25 深圳国顺康医药科技有限公司 一种杂环化合物、其药物组合物及用途
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
AU2021209057A1 (en) * 2020-01-13 2022-06-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pyrazolylpyrimidines and use thereof
WO2021155050A1 (en) * 2020-01-29 2021-08-05 Biotheryx, Inc. Kinase modulators, pharmaceutical compositions, and therapeutic applications
CA3177058A1 (en) * 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators
US20240207268A1 (en) * 2021-03-24 2024-06-27 Biotheryx, Inc. Pyrazolylpyrimidines for treating malignant solid tumor
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11752151B2 (en) * 2021-07-12 2023-09-12 Buddhist Tzu Chi Medical Foundation Method for enhancing hair growth
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2025199440A1 (en) * 2024-03-21 2025-09-25 Edgewood Oncology Methods of treating liposarcoma using a pyrazole compound
WO2025199434A1 (en) * 2024-03-21 2025-09-25 Edgewood Oncology Methods of treating breast cancer using a pyrazole compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430539C (en) 2000-12-05 2010-07-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP4316893B2 (ja) 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Srcおよび他のプロテインキナーゼのインヒビター
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2005095357A2 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
JP2007145819A (ja) 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20100063049A1 (en) 2006-05-26 2010-03-11 Clifford Jones 2-carbocycloamino-4-imidazolylpyrimidines as agents for the inhbition of cell proliferation
EP2231636B1 (en) 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
BR112014010563B1 (pt) 2011-11-04 2021-01-12 Jasco Pharmaceuticals, LLC compostos inibidores da aminopirimidina quinase
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AU2014337044A1 (en) * 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
RS62728B1 (sr) 2015-08-04 2022-01-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivat pirazol pirimidina i njegove upotrebe
WO2018142393A1 (en) * 2017-02-01 2018-08-09 Yissum Research Development Company Of The Hebrew N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer
KR20200130287A (ko) 2018-02-08 2020-11-18 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도

Also Published As

Publication number Publication date
RU2018107668A3 (pl) 2020-01-13
EP3331877A1 (en) 2018-06-13
PT3331877T (pt) 2021-12-27
US10376511B2 (en) 2019-08-13
KR20180043794A (ko) 2018-04-30
ZA201800671B (en) 2020-05-27
SI3331877T1 (sl) 2022-02-28
HRP20211949T1 (hr) 2022-03-18
KR102698366B1 (ko) 2024-08-26
AU2021200839A1 (en) 2021-03-04
US20210251992A1 (en) 2021-08-19
NZ739511A (en) 2023-08-25
US20190365759A1 (en) 2019-12-05
ES2901349T3 (es) 2022-03-22
RS62728B1 (sr) 2022-01-31
CA2994644A1 (en) 2017-02-09
DK3331877T3 (da) 2022-01-03
CN108137562A (zh) 2018-06-08
US10960003B2 (en) 2021-03-30
SMT202100720T1 (it) 2022-01-10
US12514859B2 (en) 2026-01-06
MX384172B (es) 2025-03-14
US20180214447A1 (en) 2018-08-02
HUE057607T2 (hu) 2022-06-28
CN108137562B (zh) 2021-11-30
RU2018107668A (ru) 2019-09-05
IL257282A (en) 2018-03-29
US20250049793A1 (en) 2025-02-13
JP2018525441A (ja) 2018-09-06
IL257282B (en) 2021-06-30
CY1124898T1 (el) 2023-01-05
WO2017021969A1 (en) 2017-02-09
EP3331877B1 (en) 2021-09-22
MX2018001395A (es) 2018-04-13
RU2735522C2 (ru) 2020-11-03
AU2016304464A1 (en) 2018-02-22
AU2016304464B2 (en) 2020-11-19
JP7083309B2 (ja) 2022-06-10
LT3331877T (lt) 2022-01-10
US11925641B2 (en) 2024-03-12
HK1256535A1 (en) 2019-09-27

Similar Documents

Publication Publication Date Title
ZA201800671B (en) Pyrazole pyrimidine derivative and uses thereof
IL258180B (en) Heterocyclic compounds and their uses
IL259150B (en) Pyrimidine derivative and use thereof
EP3099677A4 (en) Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3268362A4 (en) Substituted pyridines and uses thereof
EP3097078A4 (en) Pyridines and pyrimidines and use thereof
IL247426A0 (en) Pyrazole amide derivatives, preparations containing them and their uses
PT3357922T (pt) Composto de pirimidina ou piridopiridona e sua aplicação
SG11201706029VA (en) Anti-senescence compounds and uses thereof
IL246630B (en) History of pyrimidine pyrazolyl and pharmaceutical preparations containing them
ZA201801052B (en) Combinations and uses thereof
IL247148A0 (en) Pyrazolone compounds and uses thereof
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201504763D0 (en) Compounds and uses
SG10201913525QA (en) Pyrimidine derivative
IL254241A0 (en) Etv2 and its uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
IL253459B (en) Isoergoline compounds and their uses
GB2543375B (en) Compounds and their uses
AU201610551S (en) Wardrobe
AU2016041V (en) Primaris Diplotaxis tenuifolia
GB201514761D0 (en) Preparation and uses of pyrimidinone derivatives
EM29071470002S (pl) Walizki